Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Paolo G. Casali; Jean Yves Blay; Alexia Bertuzzi; Stefan Bielack; Bodil Bjerkehagen; Sylvie Bonvalot; Ioannis Boukovinas; Paolo Bruzzi; Angelo Paolo Dei Tos; Palma Dileo; Mikael Eriksson; Alexander Fedenko; Andrea Ferrari; Stefano Ferrari; Hans Gelderblom; Robert Grimer; Alessandro Gronchi; Rick Haas; Kirsten Sundby Hall; Peter Hohenberger; Rolf Issels; Heikki Joensuu; Ian Judson; Axel Le Cesne; Saskia Litière; Javier Martin-Broto; Ofer Merimsky; Michael Montemurro; Carlo Morosi; Piero Picci; Isabelle Ray-Coquard; Peter Reichardt; Piotr Rutkowski; Marcus Schlemmer; Silvia Stacchiotti; Valter Torri; Annalisa Trama; Frits Van Coevorden; Winette Van der Graaf; Daniel Vanel; Eva Wardelmann; Stephanie Bolle; Rodolfo Capanna; Thomas Delaney; Francesco Doglietto; Piero Fossati; Lee Jeys; Bernd Kasper; Andreas Leithner; Ole Jacob Norum; Stefano Radaelli; Susanne Scheipl; Elena Tamborini; Mathias Uhl; Carmen L.A. Vleggert-Lankamp

doi:10.1093/annonc/mdu256

Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, Jean Yves Blay, Alexia Bertuzzi, Stefan Bielack, Bodil Bjerkehagen, Sylvie Bonvalot, Ioannis Boukovinas, Paolo Bruzzi, Angelo Paolo Dei Tos, Palma Dileo, Mikael Eriksson, Alexander Fedenko, Andrea Ferrari, Stefano Ferrari, Hans Gelderblom, Robert Grimer, Alessandro Gronchi, Rick Haas, Kirsten Sundby Hall, Peter HohenbergerRolf Issels, Heikki Joensuu, Ian Judson, Axel Le Cesne, Saskia Litière, Javier Martin-Broto, Ofer Merimsky, Michael Montemurro, Carlo Morosi, Piero Picci, Isabelle Ray-Coquard, Peter Reichardt, Piotr Rutkowski, Marcus Schlemmer, Silvia Stacchiotti, Valter Torri, Annalisa Trama, Frits Van Coevorden, Winette Van der Graaf, Daniel Vanel, Eva Wardelmann, Stephanie Bolle, Rodolfo Capanna, Thomas Delaney, Francesco Doglietto, Piero Fossati, Lee Jeys, Bernd Kasper, Andreas Leithner, Ole Jacob Norum, Stefano Radaelli, Susanne Scheipl, Elena Tamborini, Mathias Uhl, Carmen L.A. Vleggert-Lankamp

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

245 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	iii113-iii123
journal	Annals of Oncology
Volume	25
Les DOIs	https://doi.org/10.1093/annonc/mdu256
état	Publié - 1 sept. 2014

Accès au document

10.1093/annonc/mdu256

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Casali, P. G., Blay, J. Y., Bertuzzi, A., Bielack, S., Bjerkehagen, B., Bonvalot, S., Boukovinas, I., Bruzzi, P., Tos, A. P. D., Dileo, P., Eriksson, M., Fedenko, A., Ferrari, A., Ferrari, S., Gelderblom, H., Grimer, R., Gronchi, A., Haas, R., Hall, K. S., ... Vleggert-Lankamp, C. L. A. (2014). Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25, iii113-iii123. https://doi.org/10.1093/annonc/mdu256

@article{e35876f3a3e8411db196e0b5bc2b0d20,

title = "Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",

author = "Casali, {Paolo G.} and Blay, {Jean Yves} and Alexia Bertuzzi and Stefan Bielack and Bodil Bjerkehagen and Sylvie Bonvalot and Ioannis Boukovinas and Paolo Bruzzi and Tos, {Angelo Paolo Dei} and Palma Dileo and Mikael Eriksson and Alexander Fedenko and Andrea Ferrari and Stefano Ferrari and Hans Gelderblom and Robert Grimer and Alessandro Gronchi and Rick Haas and Hall, {Kirsten Sundby} and Peter Hohenberger and Rolf Issels and Heikki Joensuu and Ian Judson and Cesne, {Axel Le} and Saskia Liti{\`e}re and Javier Martin-Broto and Ofer Merimsky and Michael Montemurro and Carlo Morosi and Piero Picci and Isabelle Ray-Coquard and Peter Reichardt and Piotr Rutkowski and Marcus Schlemmer and Silvia Stacchiotti and Valter Torri and Annalisa Trama and {Van Coevorden}, Frits and {Van der Graaf}, Winette and Daniel Vanel and Eva Wardelmann and Stephanie Bolle and Rodolfo Capanna and Thomas Delaney and Francesco Doglietto and Piero Fossati and Lee Jeys and Bernd Kasper and Andreas Leithner and Norum, {Ole Jacob} and Stefano Radaelli and Susanne Scheipl and Elena Tamborini and Mathias Uhl and Vleggert-Lankamp, {Carmen L.A.}",

note = "Funding Information: Stefan Bielack declared: consultancy/advisory board/speakers bureau from Merck, IDM/Takeda, Roche, Celgene, Bayer, and Chugai. Sylvie Bonvalot declared: travel grants from PharmaMar, Nanobiotix, and honoraria from Novartis. Paolo G. Casali declared: consultancy/honoraria: Amgen Dompl{\'e}, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi. Angelo Paolo Dei Tos declared: speakers{\textquoteright} bureau: Novartis Oncology, Pfizer, GlaxoSmithKline, and PharmaMar. Thomas Delaney has reported that he owned common stock in GlaxoSmithKline that was sold in early 2014; membership of the Amgen Giant Cell Tumor Global Scientific Advisory Board and received compensation for attending a meeting of this advisory board in 2012. Mikael Eriksson declared: honoraria from Novartis, Swedish Orphan Biovitrum, GlaxoSmithKline, Merck Sharp & Dohme, and Pfizer. Alexander Fedenko declared: speakers{\textquoteright} bureau: Johnson & Johnson, GlaxoSmithKline, and Roche. Stefano Ferrari declared: speakers{\textquoteright} honoraria from Takeda; advisory board for Amgen; research grants from Mulmed, Amgen, and Morphotek. Hans Gelderblom declared research grants from Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Eisai, and Bayer. Robert Grimer declared: research grant: Amgen. Alessandro Gronchi declared: advisory board: Novartis; honoraria: Novartis and Pfizer. Rolf Issels declared: consultancy/honoraria: PharmaMar, Bayer, and Therm Med. Heikki Joensuu declared: research funding to institute from Novartis. Bernd Kasper declared: consultancy/honoraria: Novartis, GlaxoSmithKline, and PharmaMar; research grants: PharmaMar. Axel Le Cesne declared: honoraria: Novartis, PharmaMar, GlaxoSmithKline, and Pfizer. Javier Martin-Broto declared advisory boards for GlaxoSmithKline, Novartis, and PharmaMar. Ofer Merimsky declared: speakers{\textquoteright} honoraria: GlaxoSmithKline and Lilly; advisory board: Boehringer Ingelheim and Medison; research grant: Roche. Piero Picci declared advisory board for Takeda. Piotr Rutkowski declared honoraria from Novartis, Pfizer, Bristol-Myers Squibb, Roche, and GlaxoSmithKline; advisory board for Novartis, GlaxoSmithKline, Merck Sharp & Dohme, and Bayer. Susanne Scheipl declared grants and personal fees from the Chordoma Foundation, as well as non-financial support from GlaxoSmithKline, and non-financial support from PharmaMar in course of her current research project on chordoma at the UCL Cancer Institute in London. Marcus Schlemmer declared: honoraria from Novartis, Pfizer, and Teva; research grants from Novartis. Silvia Stacchiotti declared: research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, and Bayer. Frits Van Coevorden declared travel grants from Novartis and PharmaMar. Carmen Vleggeert-Lankamp declared research grants from Medtronic, B Braun, Paradigm Spine and the Eurospine Foundation, the National Health Organization, Netherlands, and the Dutch Brain Foundation. Winette Van der Graaf declared: research funding from GlaxoSmithKline, Novartis and Pfizer. The following authors have declared no potential conflicts of interest: Alexia Bertuzzi, Bodil Bjerkehagen, Stephanie Bolle, Ioannis Boukovinas, Rodolfo Capanna, Palma Dileo, Francesco Doglietto, Andrea Ferrari, Piero Fossati, Rick Haas, Kirsten Sundby Hall, Lee Jeys, Andreas Leithner, Saskia Liti{\`e}re, Michael Montemurro, Carlo Morosi, Stefano Radaelli, Isabelle Ray-Coquard, Elena Tamborini, Valter Torri, Daniel Vanel and Eva Wardelmann. The other authors have not reported any potential conflicts of interest.",

year = "2014",

month = sep,

day = "1",

doi = "10.1093/annonc/mdu256",

language = "English",

volume = "25",

pages = "iii113--iii123",

journal = "Annals of Oncology",

issn = "0923-7534",

}

Casali, PG, Blay, JY, Bertuzzi, A, Bielack, S, Bjerkehagen, B, Bonvalot, S, Boukovinas, I, Bruzzi, P, Tos, APD, Dileo, P, Eriksson, M, Fedenko, A, Ferrari, A, Ferrari, S, Gelderblom, H, Grimer, R, Gronchi, A, Haas, R, Hall, KS, Hohenberger, P, Issels, R, Joensuu, H, Judson, I, Cesne, AL, Litière, S, Martin-Broto, J, Merimsky, O, Montemurro, M, Morosi, C, Picci, P, Ray-Coquard, I, Reichardt, P, Rutkowski, P, Schlemmer, M, Stacchiotti, S, Torri, V, Trama, A, Van Coevorden, F, Van der Graaf, W, Vanel, D, Wardelmann, E, Bolle, S, Capanna, R, Delaney, T, Doglietto, F, Fossati, P, Jeys, L, Kasper, B, Leithner, A, Norum, OJ, Radaelli, S, Scheipl, S, Tamborini, E, Uhl, M & Vleggert-Lankamp, CLA 2014, 'Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up', Annals of Oncology, VOL. 25, p. iii113-iii123. https://doi.org/10.1093/annonc/mdu256

TY - JOUR

T1 - Bone sarcomas

T2 - ESMO clinical practice guidelines for diagnosis, treatment and follow-up

AU - Casali, Paolo G.

AU - Blay, Jean Yves

AU - Bertuzzi, Alexia

AU - Bielack, Stefan

AU - Bjerkehagen, Bodil

AU - Bonvalot, Sylvie

AU - Boukovinas, Ioannis

AU - Bruzzi, Paolo

AU - Tos, Angelo Paolo Dei

AU - Dileo, Palma

AU - Eriksson, Mikael

AU - Fedenko, Alexander

AU - Ferrari, Andrea

AU - Ferrari, Stefano

AU - Gelderblom, Hans

AU - Grimer, Robert

AU - Gronchi, Alessandro

AU - Haas, Rick

AU - Hall, Kirsten Sundby

AU - Hohenberger, Peter

AU - Issels, Rolf

AU - Joensuu, Heikki

AU - Judson, Ian

AU - Cesne, Axel Le

AU - Litière, Saskia

AU - Martin-Broto, Javier

AU - Merimsky, Ofer

AU - Montemurro, Michael

AU - Morosi, Carlo

AU - Picci, Piero

AU - Ray-Coquard, Isabelle

AU - Reichardt, Peter

AU - Rutkowski, Piotr

AU - Schlemmer, Marcus

AU - Stacchiotti, Silvia

AU - Torri, Valter

AU - Trama, Annalisa

AU - Van Coevorden, Frits

AU - Van der Graaf, Winette

AU - Vanel, Daniel

AU - Wardelmann, Eva

AU - Bolle, Stephanie

AU - Capanna, Rodolfo

AU - Delaney, Thomas

AU - Doglietto, Francesco

AU - Fossati, Piero

AU - Jeys, Lee

AU - Kasper, Bernd

AU - Leithner, Andreas

AU - Norum, Ole Jacob

AU - Radaelli, Stefano

AU - Scheipl, Susanne

AU - Tamborini, Elena

AU - Uhl, Mathias

AU - Vleggert-Lankamp, Carmen L.A.

N1 - Funding Information: Stefan Bielack declared: consultancy/advisory board/speakers bureau from Merck, IDM/Takeda, Roche, Celgene, Bayer, and Chugai. Sylvie Bonvalot declared: travel grants from PharmaMar, Nanobiotix, and honoraria from Novartis. Paolo G. Casali declared: consultancy/honoraria: Amgen Domplé, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi. Angelo Paolo Dei Tos declared: speakers’ bureau: Novartis Oncology, Pfizer, GlaxoSmithKline, and PharmaMar. Thomas Delaney has reported that he owned common stock in GlaxoSmithKline that was sold in early 2014; membership of the Amgen Giant Cell Tumor Global Scientific Advisory Board and received compensation for attending a meeting of this advisory board in 2012. Mikael Eriksson declared: honoraria from Novartis, Swedish Orphan Biovitrum, GlaxoSmithKline, Merck Sharp & Dohme, and Pfizer. Alexander Fedenko declared: speakers’ bureau: Johnson & Johnson, GlaxoSmithKline, and Roche. Stefano Ferrari declared: speakers’ honoraria from Takeda; advisory board for Amgen; research grants from Mulmed, Amgen, and Morphotek. Hans Gelderblom declared research grants from Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Eisai, and Bayer. Robert Grimer declared: research grant: Amgen. Alessandro Gronchi declared: advisory board: Novartis; honoraria: Novartis and Pfizer. Rolf Issels declared: consultancy/honoraria: PharmaMar, Bayer, and Therm Med. Heikki Joensuu declared: research funding to institute from Novartis. Bernd Kasper declared: consultancy/honoraria: Novartis, GlaxoSmithKline, and PharmaMar; research grants: PharmaMar. Axel Le Cesne declared: honoraria: Novartis, PharmaMar, GlaxoSmithKline, and Pfizer. Javier Martin-Broto declared advisory boards for GlaxoSmithKline, Novartis, and PharmaMar. Ofer Merimsky declared: speakers’ honoraria: GlaxoSmithKline and Lilly; advisory board: Boehringer Ingelheim and Medison; research grant: Roche. Piero Picci declared advisory board for Takeda. Piotr Rutkowski declared honoraria from Novartis, Pfizer, Bristol-Myers Squibb, Roche, and GlaxoSmithKline; advisory board for Novartis, GlaxoSmithKline, Merck Sharp & Dohme, and Bayer. Susanne Scheipl declared grants and personal fees from the Chordoma Foundation, as well as non-financial support from GlaxoSmithKline, and non-financial support from PharmaMar in course of her current research project on chordoma at the UCL Cancer Institute in London. Marcus Schlemmer declared: honoraria from Novartis, Pfizer, and Teva; research grants from Novartis. Silvia Stacchiotti declared: research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, and Bayer. Frits Van Coevorden declared travel grants from Novartis and PharmaMar. Carmen Vleggeert-Lankamp declared research grants from Medtronic, B Braun, Paradigm Spine and the Eurospine Foundation, the National Health Organization, Netherlands, and the Dutch Brain Foundation. Winette Van der Graaf declared: research funding from GlaxoSmithKline, Novartis and Pfizer. The following authors have declared no potential conflicts of interest: Alexia Bertuzzi, Bodil Bjerkehagen, Stephanie Bolle, Ioannis Boukovinas, Rodolfo Capanna, Palma Dileo, Francesco Doglietto, Andrea Ferrari, Piero Fossati, Rick Haas, Kirsten Sundby Hall, Lee Jeys, Andreas Leithner, Saskia Litière, Michael Montemurro, Carlo Morosi, Stefano Radaelli, Isabelle Ray-Coquard, Elena Tamborini, Valter Torri, Daniel Vanel and Eva Wardelmann. The other authors have not reported any potential conflicts of interest.

PY - 2014/9/1

Y1 - 2014/9/1

UR - http://www.scopus.com/inward/record.url?scp=84911463658&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu256

DO - 10.1093/annonc/mdu256

M3 - Article

C2 - 25210081

AN - SCOPUS:84911463658

SN - 0923-7534

VL - 25

SP - iii113-iii123

JO - Annals of Oncology

JF - Annals of Oncology

ER -